Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mannatech results

This article was originally published in The Tan Sheet

Executive Summary

Dietary supplement direct seller reports consolidated net sales increase of 35.6% to $191 mil. in 2003, as income more than tripled over the prior year to $8.8 mil. Coppell, Texas-based company recorded sales of $54.3 mil. in the fourth quarter, up 9.2% over same period in 2002. Mannatech attributes improved annual performance in part to antioxidant product Ambrotose AO, launched last September (1"The Tan Sheet" Nov. 17, 2003, In Brief). Firm plans launches in South Korea in second half of 2004 and Taiwan in first quarter 2005...

You may also be interested in...



Mannatech

September launch of Ambrotose A.O. antioxidant supplement helps boost revenues 44.1% to $49.7 mil. for the third quarter ended Sept. 30 versus the prior-year period, Coppell, Texas-based direct marketer reports Nov. 7. CEO Sam Caster believes the product could total 25% of Mannatech's gross sales by 2005 (1"The Tan Sheet" Aug. 25, 2003, p. 15). Mannatech's net income rose to $2.9 mil. compared with $200,000 in the year-ago period...

FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility

The US FDA’s device center has unveiled a new public dataset designed to assist chemistry laboratories in ensuring the robustness of chemical characterization methods used to assess the biocompatibility of medical devices.

Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line

The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS096586

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel